Immuno-Oncology | Specialty

Isolated Progression of NSCLC on Immunotherapy

September 28th 2017

The Potential for IO Use as Maintenance Therapy in NSCLC

September 28th 2017

Duration of Upfront Immunotherapy for NSCLC

September 28th 2017

Patient Selection for Upfront Immunotherapy in NSCLC

September 28th 2017

Upfront PD-L1 Blockade in Newly Diagnosed NSCLC

September 28th 2017

NSCLC Immunotherapy: Transformation of Upfront Therapy

September 28th 2017

Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies

September 28th 2017

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

Avelumab Approved in Japan for Merkel Cell Carcinoma

September 27th 2017

The Japanese Ministry of Health, Labor and Welfare has approved avelumab (Bavencio) for use in patients with metastatic Merkel cell carcinoma, according to Merck KGaA.

Pal Provides Key ESMO Updates in GU Malignancies

September 26th 2017

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Relatlimab/Nivolumab Combo Active in Melanoma After PD-1/PD-L1 Therapy

September 26th 2017

Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.

Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC

September 26th 2017

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25th 2017

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

FDA Approves Nivolumab for Hepatocellular Carcinoma

September 23rd 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib.

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

September 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

COMBI-AD: Implications for Melanoma Patients

September 22nd 2017

A New Standard for Stage 3 BRAF+ Melanoma

September 22nd 2017

Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21st 2017

The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

September 20th 2017

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.